|
| 36218318 | An environmental scan of sexual health services for cancer survivors among Canadian institutions. | Can Urol Assoc J | 2023 |
| 37497748 | Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out? | Curr Opin Urol | 2023 |
| 37969642 | Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. | JACC CardioOncol | 2023 |
| 35750582 | Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. | Eur Urol | 2023 |
| 37326757 | Living with prostate cancer: a mixed-method evaluation of group therapy intervention to alleviate psychological distress in a Canadian setting. | Support Care Cancer | 2023 |
| 36948505 | First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). | J Immunother Cancer | 2023 |
| 37251627 | Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. | EClinicalMedicine | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 36472138 | Adherence With Oral Anticancer Therapies: Clinical Trial vs Real-world Experiences With a Focus on Prostate Cancer. | J Urol | 2023 |
| 36763954 | A randomized comparison of group mindfulness and group cognitive behavioral therapy vs control for couples after prostate cancer with sexual dysfunction. | J Sex Med | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34368888 | Cognitive skill training improves memory, function, and use of cognitive strategies in cancer survivors. | Support Care Cancer | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35378840 | Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach. | J Bone Oncol | 2022 |
| 35460401 | Clinical Validation of a Circulating Tumor Cell Assay Using Density Centrifugation and Automated Immunofluorescence Microscopy. | Am J Clin Pathol | 2022 |
| 36212187 | Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. | Prostate Cancer | 2022 |
| 36192299 | Guidelines for Sexual Health Care for Prostate Cancer Patients: Recommendations of an International Panel. | J Sex Med | 2022 |
| 35190653 | Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). | Prostate Cancer Prostatic Dis | 2022 |
| 35247924 | A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 35200566 | Feasibility, Acceptability, and Clinical Significance of a Dyadic, Web-Based, Psychosocial and Physical Activity Self-Management Program (<i>TEMPO</i>) Tailored to the Needs of Men with Prostate Cancer and Their Caregivers: A Multi-Center Randomized Pilot Trial. | Curr Oncol | 2022 |
| 34993496 | Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. | HGG Adv | 2022 |
| 34990293 | Exercise Recommendation for People With Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals. | JCO Oncol Pract | 2022 |
| 34958238 | Editorial Comment. | J Urol | 2022 |
| 34613474 | Sexual rehabilitation recommendations for prostate cancer survivors and their partners from a biopsychosocial Prostate Cancer Supportive Care Program. | Support Care Cancer | 2022 |
| 34636627 | Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. | Future Oncol | 2022 |
| 34848822 | Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. | Prostate Cancer Prostatic Dis | 2022 |
| 34621011 | Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. | Prostate Cancer Prostatic Dis | 2022 |
| 33090917 | Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. | J Urol | 2021 |
| 33744812 | A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. | ESMO Open | 2021 |
| 33529815 | Preliminary Development of a Mindfulness-Based Group Therapy to Expand Couples' Sexual Intimacy after Prostate Cancer: A Mixed Methods Approach. | Sex Med | 2021 |
| 34516663 | Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. | Prostate | 2021 |
| 34459214 | Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. | Circulation | 2021 |
| 34598946 | Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. | Clin Cancer Res | 2021 |
| 34388386 | Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. | Lancet Oncol | 2021 |
| 34503355 | Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort. | J Urol | 2021 |
| 34129025 | Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. | JAMA Netw Open | 2021 |
| 34292336 | Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. | JAMA Netw Open | 2021 |
| 34108181 | A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer. | Clin Cancer Res | 2021 |
| 33390282 | The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. | Eur Urol | 2021 |
| 30528887 | Introduction to the seminar series: Optimal management during ADT to mitigate complications. | Urol Oncol | 2020 |
| 34396210 | Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design. | JACC CardioOncol | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 32086346 | Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. | Clin Cancer Res | 2020 |
| 32057714 | Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. | Clin Genitourin Cancer | 2020 |
| 33112397 | Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. | JAMA Netw Open | 2020 |
| 33092185 | Clinic Utilization and Characteristics of Patients Accessing a Prostate Cancer Supportive Care Program's Sexual Rehabilitation Clinic. | J Clin Med | 2020 |
| 32606361 | Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. | Nat Rev Urol | 2020 |
| 32795228 | Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. | J Clin Oncol | 2020 |
| 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 |